RxDoctor Payments Data

Yolanda Figueroa, MD

Advanced Heart Failure and Transplant Cardiology · Humacao, PRNPI 1053521294

Payments from drug & device makers

$176,338in general payments, 2019–2025

Across 327 payments — averaging $539.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$70K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55K
  • Novartis$23K
  • AstraZeneca$19K
  • Medtronic$3K
  • Pfizer$2K
  • plus $5K from 13 others
$30,113in research payments, 2019–2025

Across 2 payments — averaging $15,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$27K
  • Novartis$3K

What the payments were for

  • Consulting fees$5,9005%
  • Speaking & faculty fees$85,13078%
  • Travel & lodging$4,7894%
  • Food & beverage$13,90213%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck22$69,965
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)119$54,802
Novartis31$23,008
AstraZeneca39$18,576
Medtronic(2 entities)27$3,106
Pfizer5$2,047
Johnson & Johnson22$1,253
Boehringer Ingelheim11$751
Amgen9$633
Abbott9$518
E.r. Squibb & Sons, L.L.C.9$468
Boston Scientific5$395
PBG Puerto Rico LLC13$289
Bridgebio Pharma, Inc.1$148
Bayer1$125
Pfizer Pharmaceuticals LLC1$121
Alnylam Pharmaceuticals Inc.1$89
United Therapeutics Corporation1$24
Bayer Puerto Rico Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$5,046
Medicare patients
15
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan154$112,071
JardianceEmpagliflozin94$62,972
EliquisApixaban85$58,813
XareltoRivaroxaban71$46,319
FarxigaDapagliflozin Propanediol51$31,963
BrilintaTicagrelor25$13,622
Repatha PushtronexEvolocumab14$8,579
Metoprolol Succinate279$3,387
Rosuvastatin Calcium202$1,858
Atorvastatin Calcium258$1,807
Losartan Potassium211$1,691
Candesartan Cilexetil28$1,261
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid17$1,216
Carvedilol191$1,200
Spironolactone128$932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$23,008$112,071154 claims
Boehringer IngelheimJardiance$751$62,97294 claims
PfizerEliquis$2,047$58,81385 claims
Johnson & JohnsonXarelto$1,253$46,31971 claims
AstraZenecaFarxiga, Brilinta$18,576$45,58576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Humacao

Where these figures come from

Is this you, or does something look wrong? →